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Effect of chronic metabolic acidosis on vitamin D metabolism in
humans. Bone disease may occur in disorders associated with chronic
metabolic acidosis. This has been attributed, in part, to reduced
production of I ,25(OH)2D3. Although metabolic acidosis in the vitamin
D deficient animal has been associated with a reduction in the conver-
sion of radiolabeled 25(OH)D3 to 1 ,25(OH)2D3, studies in D-replete
humans have revealed no effect of acidosis on 1 ,25(OH)2D3 metabo-
lism. To examine this issue further, we measured serum 25(OH)D,
I ,25(OH)2D, and 24,25(OH)2D levels in six healthy subjects before and
after 9 days of metabolic acidosis induced by the ingestion of ammoni-
um chloride. In four subjects, we measured the increment in serum
levels of 1 ,25(OH)2D in response to the infusion of parathyroid extract
both during control and acidosis. Serum levels of l,25(OH),D, 13.6
1.3 and 14.3 0.9 pg/mI, in control and acidosis, respectively, were not
different. The serum I ,25(OH)2D levels in control and acidosis rose to a
similar degree with the infusion of PTE. These data provide strong
evidence that metabolic acidosis does not have a substantial impact on
the synthesis of l,25(OH)2D3 metabolism in vitamin D-replete humans.
Effet de I'acidose metabolique chronique sur le métabolisme de Ia
vitamine D chez les humains. Une ostéopathie peut survenir lors des
maladies associées a une acidose metabolique chronique. Cela a hté en
partie attribué a une diminution de production de 1,25(OH)2D3. Bien
que l'acidose metabolique chez l'animal deficient en vitamine D ait été
associée avec une diminution de Ia conversion de 25(OH)D3 radiomar-
qude en l,25(OH)2D3, les etudes chez les humains replete en vitamine D
n'ont pas révélé d'effet de I'acidose sur le métabolisme de Ia
l,25(OH)2D3. Afin d'étudier ce point plus a fond, nous avons mesuré la
25(OH)D, La l,25(OH)2D et Ia 24,25(OH)2D sériques chez six sujets
normaux avant et aprés 9 jours d'acidose métabolique induite par
l'ingestion de chiorure d'ammonium. Chez quatre sujets, nous avons
mesuré l'augmentation des concentrations seriques de I ,25(OH)2D en
réponse a Ia perfusion d'extraits parathyroIdiens pendant le contrôle et
I'acidose. Les concentrations sériques de 1,25(OH)2D, 13,6 1,3 et
14,3 0,9 pg/mI, pendant le contrôle et l'acidose, respectivement,
n'étaient pas diffCrentes. Les concentrations sériques de l,25(OH)2D
pendant le contrôle et l'acidose se sont élevées d'une facon semblable
pendant Ia perfusion avec Ia PTE. Ces données sont fortement en
faveur du fait que I'acidose metabolique n'a pas d'impact substantiel
sur Ia synthese de I ,25(OH)2D3 chez les humains replete en vitamine D.
Bone disease occurs in disorders associated with chronic
metabolic acidosis [1, 2].The presence of bone disease in these
disorders has been attributed, in part, to reduced production of
l,25(OH)2D3 by the kidney. Indeed, studies in vitamin D
deficient rats and chicks have shown that the conversion of 3H-
25-(OH)D3 to 3H-1,25(OH)2D3 is reduced by metabolic acidosis
[3—5]. Studies in vitamin D-repleted humans and animals have
revealed conflicting results: Basal plasma 1 ,25(OH)D levels [6]
and the conversion of radiolabeled 25(OH)2D3 [7] to
1 ,25(OH)2D3 were not reduced by metabolic acidosis of 10 to 14
days in humans. Also, the increments in plasma levels of
1 ,25(OH)2D noted in response to a low calcium and moderately
low phosphate diet were normal in rats [8], while another study
showed that metabolic acidosis in the rat suppressed the rise in
plasma l,25(OH)2D noted in response to a low calcium diet [9].
In the latter study, acidosis did not affect the serum levels of
l,25(OH)D in rats fed a normal calcium diet.
The increased synthesis of 1 ,25(OH)2D in response to a low
calcium diet is related, in part, to increased circulating levels of
PTH [10], whereas the increased synthesis of l,25(OH)2D in
response to a low phosphate diet is not [11]. Moreover, studies
in vitamin D-deficient rats have demonstrated that metabolic
acidosis alters vitamin D metabolism by interfering with the
activation of la-hydroxylase by parathyroid hormone [12].
These data suggest that, if metabolic acidosis alters vitamin D
metabolism, it should primarily affect the increased synthesis of
1,25(OH)2D induced by parathyroid hormone. To test this
hypothesis, we measured both basal serum levels of
1 ,25(OH)2D and the changes in serum 1 ,25(OH)2D in response
to an infusion of parathyroid extract in vitamin D-replete
humans during a control period and after metabolic acidosis of 9
days duration.
The results of the present studies indicate that metabolic
acidosis for 9 days does not attenuate the increment in the
serum levels of 1 ,25(OH)2D observed in response to a parathy-
roid extract infusion nor does acidosis affect basal levels of
1,25(OH)2D in normal individuals fed a regular calcium diet.
These data cast doubt on the importance of metabolic acidosis
as a factor in reducing l,25(OH)2D3 production in humans.
Moreover, they suggest that the bone disease observed in
chronic acidotic states may not be mediated primarily by
reduced vitamin D production.
Methods
Studies were conducted in six healthy adult volunteers, ages
33 to 53 years (mean, 45 3). None of the subjects had renal
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disease, bone disease, or nephrolithiasis, or were they receiving
a medication known to affect vitamin D metabolism. The
protocol was approved by the Committee on Human Studies
and signed informed consent was obtained from all participants.
All studies were performed in the Special Diagnostic and
Therapeutic Treatment Unit of the Veterans Administration
Wadsworth Medical Center. Following a 4-day period of adap-
tation to a standard constant diet providing each day 2 g
sodium, 1 to 1.5 g phosphorus, and 1 to 1.2 g calcium, balance
observations were obtained during a 5-day control period and 9
days of metabolic acidosis induced by the ingestion of ammoni-
urn chloride, 2 mEq/kg body weight per day administered in
four divided doses. On 2 control days and 2 days of the acidotic
period, blood was obtained for measurement of 25(OH)D,
l,25(OH)2D, and 24,25(OH)2D, immunoreactive parathyroid
hormone, calcium, phosphorus, and magnesium. On the last
days of both the control and acidotic periods, a 10-hr infusion of
parathyroid extract was administered in a manner previously
described [13] to four subjects. Briefly, parathyroid extract
(PTE, Eli Lilly Co., Indianapolis, Indiana) was administered in
1000 ml of 5% dextrose in water at a dose of 1 U/kg/hr over the
10 hr from 8 A.M. to 6 P.M. The same batch of parathyroid
extract was used in all studies. The potency of 1 U of this PTE
was equivalent to 2 U of bovine 1-34 PTH (Beckman Instru-
ments, Inc., Fullerton, California) when assessed by adenylate
cyclase activation using the rat renal membrane preparation.
Blood was obtained just before the infusion and at 2-hr intervals
during the infusion for measurement of total and ionized
calcium, and l,25(OH)2D, and also at 2, 4, 6, 8 and 12 hr after
the completion of the parathyroid extract infusion for measure-
ment of l,25(OH)2D.
A study of the effect of metabolic acidosis on the renal
response to PTE, including some data from these and several
additional patients, is the subject of a separate report [14].
Analytical methods. Plasma pH and Pco2 were determined in
"arterialized" venous blood on a blood gas analyzer (Micro-
blood Model 213, Instrumentation Laboratories, Lexington,
Massachusetts) as described previously [15]. Bicarbonate con-
centration was calculated from the pH and Pco2 using the
Henderson Has selbalch equation with a pK of 6.1 and solubility
coefficient of 0.0301. Calcium was determined in blood by
EGTA titration utilizing the Automatic Calcium Analyzer (Cal-
cette, Precision Scientific Group, Chicago, Illinois) and in urine
utilizing atomic absorption spectrophotometry (Perkin Elmer
Model 303, Perkin Elmer Corp., Norwalk, Connecticut). Mag-
nesium was measured using atomic absorption spectropho-
tometry. Inorganic phosphate was measured using the method
of Fiske and Subbarow [16]. Ionized calcium was measured
using a flow through electrode (Orion Research, Cambridge,
Massachusetts). Immunoreactive parathyroid hormone was
measured using a C terminal antibody [17]. Vitamin D sterols
were measured using methods that separate the 25-(OH)D and
24,25(OH)2D metabolites derived from vitamin D2 or D3. Total
1,25(OH)2D was measured by a receptor binding assay. With
this assay, the lowest detectable level of l,25(OH)2D was 5
pglml. The sample recovery was 50 to 70%; 50% displacement
occurred at 40 pg per assay tube. Further details of these
methods have been described previously [18]. All results are
expressed as the mean SEM. Differences between periods
were determined using the student's t test for paired data.
Table 1. Blood composition in the control and acidotic periodsa
Control Metabolic acidosis
pH 7.42 0.01 7.32 0.Olb
(HCO3)p, mEqiliter 28.0 0.7 18.0 0.4b
iPTH, ni, 2 to 10 i.dEq/ml' 3.0 0.07 2.9 0.07
Total Ca, mg/dl 9.5 0.2 9.2 0.1"
Ionized Ca, mg/dl 4.5 0.1 5.1 0.1"
Phosphorus, mg/dl 3.2 0.2 3.0 0.2
Mg, mg/dl 2.1 0.1 2.0 0.1
Data are mean SEM.
b P < 0.01 compared to control.
Three of the six measurements of iPTH were arbitrarily assigned a
value of 2 dEq/m1.
d P < 0.05 compared to control.
Results
Serum values for the control and acidotic periods are shown
in Table 1. The ingestion of ammonium chloride led to a
significant fall in plasma pH from 7.42 0.01 to 7.32 0.01 and
in plasma bicarbonate concentration from 28 0.7 to 18.0 0.4
mEq/liter (P < 0.01). Serum calcium fell slightly but significant-
ly from 9.5 0.2 to 9.2 0.1 mg/dl (P < 0.05), whereas ionized
calcium rose from 4.5 0.1 to 5.1 0.1 mg/dl, (P < 0.05).
Serum inorganic phosphate and magnesium in control and
acidosis were not significantly different. Immunoreactive para-
thyroid hormone (iPTH) levels were below 3 d/Eq/ml, the level
of detection, in three patients during both the control and
acidotic periods and a value of 2 d/Eq/ml was arbitrarily
assigned in these cases to enable us to calculate an arithmetic
mean for iPTH. As seen in Table 1, iPTH levels were not
significantly different in control and acidosis. Creatinine clear-
ances in control and acidosis, 111 10 and 113 12 mI/mm,
respectively, were not significantly different.
Average daily urinary calcium and phosphorus excretion rose
from 158 18 and 966 72 mg in control to 456 48 and 1125
75 mg, respectively (P < 0.01) during the acidotic period.
Similarly, average daily urinary magnesium excretion increased
from 151 14 to 179 19 mg (P < 0.05).
Figure 1 depicts the serum l,25(OH)2D and 24,25(OH)2D
levels during control and metabolic acidosis. As can be seen,
the serum l,25(OH)2D in control and acidosis, 13.6 1.3 and
14.3 0.9 pg/mI, respectively, and the serum 24,25(OH)2D in
control and acidosis 2.7 1.2 and 2.4 1.1 ng/ml were not
significantly different. Previous studies have demonstrated that
the serum 24,25(OH)2D levels are critically dependent on the
prevailing levels of 25(OH)D [19]. As depicted in Figure 2, this
close relationship between serum 24,25(OH)2D and serum
25(OH)D was maintained in metabolic acidosis. Furthermore,
serum 25(OH)D levels in control and acidosis, 29 7 and 28 7
ng/ml, respectively, were similar.
Figure 3 depicts the effect of infusion of PTE on serum
l,25(OH)2D in the four individual subjects. As can be seen, the
response in each subject was not less in the acidotic period than
the control period, although the changes in serum 1,25(OH)2D
during PTE infusion varied among the individual subjects.
Indeed, in three subjects the increment in serum levels of
1,25(OH)2D in control and acidosis were virtually identical,
whereas in one subject the rise in serum I ,25(OH)2D was higher
in the acidotic than in the control period.
The maximal increment in ionized calcium, as determined by
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the difference between the preinfusion value and the value at
the completion of PTE infusion, averaged 0.4 0.1 mg/dl in
both the control and acidotic periods.
Discussion
The present studies indicate that prolonged metabolic acido-
sis does not impair l,25(OH)2D3 production in humans receiv-
ing a normal dietary intake of calcium. This conclusion is based
on the demonstration that basal serum 1,25(OFI)2D levels were
not reduced by metabolic acidosis and that the increase of
serum I ,25(OH)2D in response to a prolonged infusion of PTE
was not attenuated.
The basal levels of I ,25(OH)2D were relatively low, presum-
ably due to an intake of calcium that was normal but slightly
higher than average. Thus, it might be argued that a fall in
serum 1 ,25(OH)2D levels during acidosis might be difficult to
detect since the values of l,25(OH)2D in control were already
low. However, were metabolic acidosis to have a significant
impact on l,25(OH)2D3 production in humans, one would
anticipate that the increment in serum 1 ,25(OH)2D levels in
response to PTE infusion would be blunted. Indeed, studies
examining the changes in serum 1 ,25(OH)2D levels in response
to the administration of parathyroid hormone to patients with
osteoporosis or pseudohypoparathyroidism, disorders in which
defective production of 1 ,25(OH)2D3 has been postulated, have
shown a blunted increment in serum l,25(OH)2D levels [20, 21].
However, the rise in serum I ,25(OH)2D levels in the present
study were virtually identical in control and acidosis. More-
over, the more than twofold rise in serum 1 ,25(OH)2D in
response to infusion of PTE was similar to the rise observed by
others who gave parathyroid hormone to normal subjects [20—
22]. Therefore, the normal PTE induced rise in serum
1 ,25(OH)2D levels in the present study provides strong evi-
dence against a significant effect of metabolic acidosis on the
production of 1,25(OH)2D3 in humans.
The metabolic acidosis in the present study was mild in
nature; thus, it might be argued that a more severe degree of
acidosis is required to impair la hydroxylase activity. Whether
the severity of metabolic acidosis is a critical factor regulating
la hydroxylase activity in the rat or in the human is unknown.
However, in the present study, other effects on the kidney
attributable to metabolic acidosis, such as an increase in urinary
calcium and phosphorus excretion, were observed.
The results of these studies agree with previous studies in D-
replete humans showing that metabolic acidosis had no effect
on either plasma 1 ,25(OH)2D levels [6] or the conversion of
radiolabeled 25(OH)D3 [7] to 1 ,25(OH)2D3. Moreover, they are
consistent with our earlier studies in vitamin D-replete rats that
have shown that metabolic acidosis does not blunt the incre-
ment in plasma 1 ,25(OH)2D levels in response to a low calcium
and moderately low phosphate diet [8]. Indeed, in this latter
study serum levels actively rose in the acidotic rats, probably
occurring in response to a fall in serum phosphorus. Studies by
Bushinsky et al [91, however, demonstrated that the rise in
plasma 1,25(OH)2D levels noted in rats fed a low calcium diet
was inhibited by metabolic acidosis if supplemental dietary
phosphate was given to prevent a fall in serum phosphorous
concentration. Thus, it appears that severe metabolic acidosis
can reduce the 1,25(OH)2D3 generation in the rat when vitamin
D production is stimulated by either a low calcium diet [9] or by
24,25(OH)2D
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Fig. 1. Effect of metabolic acidosis on plasma levels of 1,25(OH)2D and
24,25(OH)2D in normal males. Each point represents the value for an
individual subject. The horizontal line denotes the mean value.
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Fig. 2. Relationship between serum 25(OH)D and 24,25(OH)2D levels in
control and metabolic acidosis. Symbols are: 0, control; •,acidosis.
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vitamin D deficiency [3, 4, 12]. However, data obtained in
vitamin D-replete humans consuming a normal calcium diet
would appear to be more relevant in assessing a possible
contributory role of impaired vitamin D production to the
pathogenesis of bone disease in states with chronic acidosis.
On the basis of the improvement in bone disease in individ-
uals with distal RTA during treatment with alkali and the
demonstration of reduced production of 1 ,25(OH)2D3 in the
acidotic vitamin D deficient animal, it has been postulated that
altered vitamin D levels might contribute to the pathogenesis of
the bone disease noted with metabolic acidosis [2]. However,
when considering the present and previous observation in
humans concerning vitamin D metabolism with metabolic aci-
dosis, this thesis is questioned. Whether or not alterations in the
sensitivity of bone to vitamin D may contribute to the pathogen-
esis of bone disease, however, remains open to question.
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